Elevated Plasma Fibrinogen and Increased Fibrin Turnover among Healthy Women who both Smoke and Use Low-dose Oral Contraceptives

Summary

Among users of low-dose oral contraceptives (OC), cardiovascular diseases occur mainly in smokers. The mechanisms by which OC and smoking increase the risk for arterial thrombotic risk have not been adequately explained. Epidemiological evidence suggests that changes in blood coagulation and fibrinolysis may play an important role as determinants of thrombotic events. Therefore, we have investigated the associations of OC and smoking with haemostatic variables among 194 premenopausal healthy women. Fourty women were current users of low-dose OC and 62 women were smokers. After adjustment for age and body mass index, mean values of factor XIIa, factor VII activity and antigen, fibrinogen, D-dimer, global fibrinolytic capacity were significantly higher in OC users than in non-users. Mean levels of PAI activity and t-PA antigen were significantly lower in OC users than in non-users. Smokers had significantly higher mean values of fibrinogen than non-smokers. Two-way analysis of variance showed that the differences in mean levels of fibrinogen and D-dimer between OC users and non users were restricted to smokers. The positive and significant interactions between OC use and smoking in their effects on haemostatic variables were consistent with respect to age and type of OC. These preliminary data suggest that elevated plasma levels of fibrinogen and intravascular fibrin deposition may play a role in the pathogenesis of arterial thrombotic disease among women who are both low-dose OC users and smokers.

• References

• 1 Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998; 128: 467-77.
• 2 WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicenter, case-control study. Lancet 1996; 348: 498-505.
• 3 WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202-9.
• 4 Scarabin PY. Haemostatic variables and arterial thrombotic disease: epidemiological evidence. In: Hypercoagulable states: fundamental aspects, acquired disorders, and congenital thrombophilia. Seghatchian MJ, Samama MM, Hecker SP. eds. CRC Press; 1996: 209-16.
• 5 Juhan-Vague I, Alessi MC. Fibrinolysis and risk of coronary artery disease. Fibrinolysis 1996; 10: 127-36.
• 6 Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315-26.
• 7 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogen. Acta Haematol 1957; 17: 237-46.
• 8 Scarabin PY, Van Dreden P, Bonithon-Kopp C, Orssaud G, Bara L, Conard J, Samama M. Age-related changes in factor VII activation in healthy women. Clin Sci 1988; 75: 341-3.
• 9 Boyer D, Wolf M, Rothschild C, Migaud M, Amiral J, Mannucci PM, Meyer D, Larrieu MJ. An enzyme immunoassay (Elisa) for the quantification for human factor VII. Thromb Haemost 1986; 56: 250-5.
• 10 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
• 11 Amiral J, Malmejac A, Gin H, Pannell R, Vissac AM, Seigneur M, Scarabin PY, Boisseau M, Guize L, Gurewich V. Evaluation of the fibrinolytic potential on plasma: physiological and pathological variations, and associations with cardiovascular risk factors. Fibrinolysis 1999; 10 (Suppl. 01) 1-6.
• 12 Friedewald W, Levy R, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 920-4.
• 13 Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, Nieto J, Tell GS. Cigarette smoking and progression of atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. JAMA 1998; 279: 119-24.
• 14 Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, Kuller LH. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscl Thromb Vasc Biol 1997; 17: 2167-76.
• 15 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leucocyte count with coronary heart disease. Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
• 16 Folsom AR, Wu KK, Davis CE, Conlan MG, Sorlie PD, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
• 17 Ernst E, Resch K. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
• 18 Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heat disease. Lancet 1992; 342: 84-6.
• 19 Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. Arterioscler Thromb 1993; 13: 1412-7.
• 20 Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-Dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994; 90: 2236-40.
• 21 Smith FB, Lee AJ, Fowkes FRG, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
• 22 Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost 1998; 79: 129-33.
• 23 Lee AJ, Fowkes GR, Lowe GDO, Rumley A. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscl Thromb Vasc Biol 1995; 15: 1094-7.
• 24 Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis?. Clin Sci 1995; 89: 205-14.
• 25 Smith EB, Keen A, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arterioscler Thromb 1990; 10: 263-75.
• 26 Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci USA 1982; 79: 1530-4.
• 27 Scarabin PY, Plu-Bureau G, Zitoun D, Bara L, Guize Samama MM. Changes in haemostatic variables induced by oral contraceptives containing 50 μg or 30 μg of oestrogen: absence of dose-dependent effect on PAI-1 activity. Thromb Haemost 1995; 74: 837-41.
• 28 Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speizer W. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 1996; 76: 729-34.
• 29 Scarabin PY, Vissac AM, Kirzin JM, Bourgeat P, Amiral J, Agher R, Guize L. Population correlates of coagulation factor VII : importance of age, gender, and menopausal status as determinants of activated factor VII. Arterioscl Thromb Vasc Biol 1996; 16: 1170-6.
• 30 Meade TW, Haines AP, North WRS, Chakrabarti R, Howarth DJ, Stirling Y. Haemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 μg and 30 μg oestrogen. Lancet 1977; 2: 948-51.
• 31 Balleisen L, Bailey J, Epping PH, Schulte H, Van de Loo J. Epidemiological study on factor VII, factor VIII, fibrinogen in an industrial population: I Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill using ang menopause. Thromb Haemost 1985; 54: 475-9.
• 32 Plu-Bureau G, Amiral J, Guize L, Scarabin PY. Safety of combined oral contraceptive pills. Lancet 1996; 347: 549.
• 33 Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomised controlled trial. Arterioscl Thromb Vasc Biol 1997; 17: 3071-8.
• 34 Rosing J, Tans G, Nicolaes GAF, Thomassen MCLGD, van Oerle R, van der Ploeg PMEN, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
• 35 Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR. Vandenbroucke Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997; 78: 327-33.
• 36 Jespersen J, Gram J. Increased fibrin formation in blood in women above the age of 30 who are both oral contraceptives users and smokers. Fibrinolysis 1996; 10: 9-13.
• 37 Behague I, Poirier O, Nicaud V, Evans AE, Arveiler D, Luc G, Cambou JP, Scarabin PY, Bara L, Green F, Cambien F. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction – The ECTIM Study. Circulation 1996; 93: 440-9.
• 38 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
• 39 Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women. A statement for heathcare professionals from the American Heart Association. Circulation 1997; 96: 2468-82.